A regional drug regulator executive said 316 adults who had received AstraZeneca’s (AZN.L)’s AstraZeneca’s (AZN.L) COVID-19 vaccine had rare blood clots and low platelets.
The figures as of Thursday included 174 new reports since the European Medicines Agency (EMA) provided an update in April, said Georgy Genov, head of watchdog safety operations. said during a briefing on Friday.
The EMA has investigated cases of symptomatic thrombosis. thrombocytopenia syndrome (TTS) since March and a possible link has been found to a vaccine developed jointly with the University of Oxford, Vaxzevria and a single injection of Johnson & Johnson (JNJ.N).
However, it has been confirmed that the overall benefits of both vaccines outweigh any risks. caused by the vaccine
Genov said another 19 million people have received their first Vaxzevria vaccine in the EEA since the April update. He added that the frequency of TTS was unchanged. but still very rare But the mortality rate according to symptoms has decreased.
He said the lower mortality rate may indicate that awareness among vaccinated and vaccinated and treatable patients is increasing, leading to early diagnosis and treatment.
The European Economic Area consists of 27 countries in the European Union. including Iceland, Norway and Liechtenstein.
Our Standard: Thomson Reuters Trust Principles